Supernus Pharmaceuticals Inc
SUPN51.570USD
-0.200-0.39%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
2.95BCap. mercado
PérdidaP/E TTM
Más Datos de Supernus Pharmaceuticals Inc Compañía
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Información de Supernus Pharmaceuticals Inc
Símbolo de cotizaciónSUPN
Nombre de la empresaSupernus Pharmaceuticals Inc
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoKhattar (Jack A)
Número de empleados674
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 28
Dirección9715 Key West Avenue
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono13018382500
Sitio Webhttps://www.supernus.com
Símbolo de cotizaciónSUPN
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoKhattar (Jack A)
Ejecutivos de Supernus Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
10.67K
+10.74%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
901.00
-92.89%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.21M
+2.76%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Otro
15.60M
9.43%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
165.45M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Net product sales-Qelbree
77.55M
46.87%
Net product sales - GOCOVRI
36.66M
22.16%
Net product sales-APOKYN
12.82M
7.75%
Net product sales- Oxtellar XR
11.64M
7.03%
Net product sales- Trokendi XR
11.19M
6.77%
Otro
15.60M
9.43%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Otro
61.56%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.33%
The Vanguard Group, Inc.
10.52%
Dimensional Fund Advisors, L.P.
5.24%
Armistice Capital LLC
4.95%
Nomura Investment Management Business Trust
4.42%
Otro
61.56%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
51.64%
Investment Advisor/Hedge Fund
25.75%
Hedge Fund
20.25%
Individual Investor
4.29%
Research Firm
3.21%
Pension Fund
1.48%
Venture Capital
1.19%
Bank and Trust
0.63%
Sovereign Wealth Fund
0.10%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
575
60.19M
104.97%
-3.36M
2025Q2
565
63.61M
113.46%
-2.51M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
8.01M
14.29%
-191.39K
-2.33%
Jun 30, 2025
The Vanguard Group, Inc.
6.19M
11.04%
+41.36K
+0.67%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.02M
5.39%
+117.48K
+4.05%
Jun 30, 2025
Armistice Capital LLC
4.81M
8.58%
-384.00K
-7.39%
Jun 30, 2025
Nomura Investment Management Business Trust
2.76M
4.93%
+62.46K
+2.31%
Jun 30, 2025
Khattar (Jack A)
2.15M
3.84%
+54.63K
+2.60%
Sep 30, 2025
State Street Investment Management (US)
2.21M
3.94%
+63.21K
+2.95%
Jun 30, 2025
Renaissance Technologies LLC
1.66M
2.95%
+69.60K
+4.39%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AdvisorShares Psychedelics ETF
7.48%
iShares Neuroscience and Healthcare ETF
3.83%
Invesco Pharmaceuticals ETF
3.32%
State Street SPDR S&P Pharmaceuticals ETF
3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.21%
Invesco S&P SmallCap Health Care ETF
1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Lattice Hartford Multifactor Small Cap ETF
1.3%
iShares U.S. Pharmaceuticals ETF
1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
0.68%
Ver más
AdvisorShares Psychedelics ETF
Proporción7.48%
iShares Neuroscience and Healthcare ETF
Proporción3.83%
Invesco Pharmaceuticals ETF
Proporción3.32%
State Street SPDR S&P Pharmaceuticals ETF
Proporción3.11%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.21%
Invesco S&P SmallCap Health Care ETF
Proporción1.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción1.63%
Lattice Hartford Multifactor Small Cap ETF
Proporción1.3%
iShares U.S. Pharmaceuticals ETF
Proporción1.14%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.68%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Supernus Pharmaceuticals Inc?
Los cinco principales accionistas de Supernus Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A. posee 8.01M acciones, lo que representa el 14.29% del total de acciones.
The Vanguard Group, Inc. posee 6.19M acciones, lo que representa el 11.04% del total de acciones.
Dimensional Fund Advisors, L.P. posee 3.02M acciones, lo que representa el 5.39% del total de acciones.
Armistice Capital LLC posee 4.81M acciones, lo que representa el 8.58% del total de acciones.
Nomura Investment Management Business Trust posee 2.76M acciones, lo que representa el 4.93% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.01M acciones, lo que representa el 14.29% del total de acciones.
The Vanguard Group, Inc. posee 6.19M acciones, lo que representa el 11.04% del total de acciones.
Dimensional Fund Advisors, L.P. posee 3.02M acciones, lo que representa el 5.39% del total de acciones.
Armistice Capital LLC posee 4.81M acciones, lo que representa el 8.58% del total de acciones.
Nomura Investment Management Business Trust posee 2.76M acciones, lo que representa el 4.93% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Supernus Pharmaceuticals Inc?
Los tres principales tipos de accionista de Supernus Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Dimensional Fund Advisors, L.P.
¿Cuántas instituciones poseen acciones de Supernus Pharmaceuticals Inc (SUPN)?
A fecha de 2025Q3, 575 instituciones poseen acciones de Supernus Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 60.19M, lo que representa el 104.97% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -8.49%.
¿Cuál es la mayor fuente de ganancias de Supernus Pharmaceuticals Inc?
El FY2025Q2, el segmento empresarial Net product sales-Qelbree generó la ganancia más alta para Supernus Pharmaceuticals Inc, ascendiendo a 77.55M y representando el 46.87% de la ganancia total.
